G47Δ-mAngio

G47Δ-mAngio is an **oncolytic herpes simplex virus (oHSV)** genetically engineered to express **mouse angiostatin**, a potent antiangiogenic polypeptide. It is derived from the G47Δ backbone—an advanced (third-generation) oncolytic herpesvirus with deletions such as ICP47—which has shown clinical efficacy in malignant glioma. The mechanism harnesses the tumor-selective lytic activity of the oHSV together with the antiangiogenic effects of angiostatin, thereby restricting tumor blood vessel formation and enhancing therapeutic effects against highly vascularized tumors such as glioblastoma. In preclinical glioma models, intratumoral administration of G47Δ-mAngio significantly prolonged survival compared to vector controls, attenuated tumor vascularity, decreased macrophage infiltration, and increased virus distribution within the tumor. G47Δ-mAngio has also been tested in combination with other armed oHSV vectors, such as G47Δ-mIL12, for further potentiated antiangiogenic and antitumor effects[1][3].